JP2016532647A5 - - Google Patents

Download PDF

Info

Publication number
JP2016532647A5
JP2016532647A5 JP2016520627A JP2016520627A JP2016532647A5 JP 2016532647 A5 JP2016532647 A5 JP 2016532647A5 JP 2016520627 A JP2016520627 A JP 2016520627A JP 2016520627 A JP2016520627 A JP 2016520627A JP 2016532647 A5 JP2016532647 A5 JP 2016532647A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016520627A
Other languages
English (en)
Japanese (ja)
Other versions
JP6348582B2 (ja
JP2016532647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/064836 external-priority patent/WO2015052610A1/en
Publication of JP2016532647A publication Critical patent/JP2016532647A/ja
Publication of JP2016532647A5 publication Critical patent/JP2016532647A5/ja
Application granted granted Critical
Publication of JP6348582B2 publication Critical patent/JP6348582B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016520627A 2013-10-09 2014-09-25 プロスタグランジンep3受容体の拮抗薬 Expired - Fee Related JP6348582B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361888822P 2013-10-09 2013-10-09
US61/888,822 2013-10-09
PCT/IB2014/064836 WO2015052610A1 (en) 2013-10-09 2014-09-25 Antagonists of prostaglandin ep3 receptor

Publications (3)

Publication Number Publication Date
JP2016532647A JP2016532647A (ja) 2016-10-20
JP2016532647A5 true JP2016532647A5 (https=) 2017-10-26
JP6348582B2 JP6348582B2 (ja) 2018-06-27

Family

ID=51900918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016520627A Expired - Fee Related JP6348582B2 (ja) 2013-10-09 2014-09-25 プロスタグランジンep3受容体の拮抗薬

Country Status (9)

Country Link
US (1) US9278953B2 (https=)
EP (1) EP3055300B1 (https=)
JP (1) JP6348582B2 (https=)
AR (1) AR097963A1 (https=)
CA (1) CA2926568C (https=)
ES (1) ES2665153T3 (https=)
TW (1) TW201527297A (https=)
UY (1) UY35776A (https=)
WO (1) WO2015052610A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3237401B1 (en) * 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
US10590083B2 (en) 2017-08-10 2020-03-17 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists
US10399944B2 (en) 2017-08-10 2019-09-03 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists
US10336701B2 (en) * 2017-08-10 2019-07-02 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists
EP3793559A1 (en) 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP4319734A2 (en) 2021-04-07 2024-02-14 Hadasit Medical Research Services&Development Ltd. Prostaglandin receptor 3 (ep3) antagonists for use in the treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
CN1642599A (zh) 2002-02-27 2005-07-20 辉瑞产品公司 Acc抑制剂
PL1753748T3 (pl) 2004-05-12 2010-01-29 Pfizer Prod Inc Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2007027630A2 (en) 2005-08-30 2007-03-08 Smithkline Beecham Corporation Genes associated with type ii diabetes mellitus
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
BRPI0721053A2 (pt) 2006-11-29 2014-07-29 Pfizer Prod Inc INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
WO2009144555A1 (en) 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
EP2604604A1 (en) 2009-03-11 2013-06-19 Pfizer Inc Benzofuranyl derivatives used as glucokinase inhibitors
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2016532647A5 (https=)
JP2017071634A5 (https=)
JP2017520613A5 (https=)
JP2017509586A5 (https=)
JP2016518328A5 (https=)
JP2019524883A5 (https=)
JP2017105793A5 (https=)
JP2016515561A5 (https=)
JOP20190077A1 (ar) مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JP2016523270A5 (https=)
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
WO2016205475A3 (en) Tgr5 modulators and methods of use thereof
JP2016505010A5 (https=)
JP2017517512A5 (https=)
JP2012092103A5 (https=)
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
JP2016530259A5 (https=)
WO2016098054A9 (en) Processes for preparing oxathiazin-like compounds
JP2016505637A5 (https=)
JP2015504909A5 (https=)
JP2016540749A5 (https=)
JP2018521020A5 (https=)
CY1121123T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
JP2016540803A5 (https=)